🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Generic cancer drugs are already in short supply. The Inflation Reduction Act makes it harder to develop new cancer drugs that could help this crisis. "We're at a crisis point - literally today." - Rep. Brian Fitzpatrick 🇺🇸

The #PASTEURAct would expand #antibiotic stewardship programs to support smaller, rural hospitals, Arielle Dreher reports for Axios axios.com/2023/07/12/inf…

“We have seen the number of companies, especially the larger companies, decline from 20 or so down to just a handful who are still even in the [#antibiotic development] space,” Jocelyn Ulrich, MPH says of the market failure for new antibiotics. @JaimieSeaton scientificamerican.com/article/ai-cou…

“In residency, I saw firsthand how #antibiotics were integral to so many different medical specialties–and also how these drugs were no longer working the way they used to.” – UofL Med School’s Dr. Bethany Wattles. pew.org/3O9Eo2b

Discuss implications of policy impact on biomedical innovation at the Longwood Fund #LongwoodHealthcareLeaders Fall Conference at Harvard Med. Join the conversation with Biogen Ovid Therapeutics PhRMA Cambrian and others longwoodhealthcareleaders.com/fall2023

The best kind of chaos and violence.

Given what we *know* about size of rebates in this space -- it's irresponsible to write articles or tables that lead with list price and put in a caveat that there "may" be rebates. Even having a table with only list prices is writing click bait and not careful analysis.

Hear from Industry Leaders at the Longwood Fall Conference September 18-19 conta.cc/3Pbjfq7

Tears. This is incredible. Must watch.

.Craig Garthwaite spoke to The New York Times about the cost of new weight-loss drugs. "We spent 15 years talking about the soaring cost of obesity" to healthcare but the attitude of some insurers seems to be, “we don’t want you to come up with a fix that costs money.” spr.ly/6017uYSwJ

Join us this Friday in Harbor East, Baltimore! Reg. link: lnkd.in/g_4YXBV9. Organized by Supriya Munshaw Mariana Socal So-Yeon Kang & myself. Speakers include: Tanisha Carino Anna Kaltenboeck Sally Allain Josh Bilenker, M.D. Holly Fernandez Lynch Leigh Purvis Joshua Sharfstein Jocelyn Ulrich, MPH

Newly approved gene therapies represent monumental breakthroughs for patients. Unfortunately, President Donald J. Trump is celebrating these innovations just days after proposing policies that undermine the very IP framework that made these life-changing treatments possible. finance.yahoo.com/news/biden-pra…

As Wall Street Journal Opinion points out, the administration's recent proposal to abuse "march-in" rights — and upend America's longstanding system of public-private partnerships — is fundamentally at odds with initiatives like the Cancer Moonshot.

The biopharmaceutical research industry depends on a highly skilled workforce with knowledge and experience in STEM yet 90% of surveyed research companies experience difficulties recruiting the qualified talent they need. That's why the industry is making a sustained investment.

FIVE polling places in Fulton County, GA have extended their polling hours. If you live in Fulton County, find your polling place at WeAll.Vote/voterhub and go VOTE! 🗳️ 🏃

So when I hear demagogues denounce "Big Pharma," I append my own branding: "Big Pharma. The people who rescue children from leukemia." END

We’re live at the inaugural PhRMA Forum, where we’re unveiling critical initiatives, including our latest Innovation Report, and engaging in meaningful discussions with industry leaders and patient advocates. This is an important moment as we work together to shape the future of

Growing Texas measles outbreak spreads to second state: What to know newsweek.com/measles-outbre…

The IRA’s price-setting policies and PBM efforts to block biosimilar competition jeopardize the market's progress in increasing patients’ treatment options. Our VP of Policy and Research, Jocelyn Ulrich, MPH, recently discussed alongside Amgen 🧪🔬🧬 how we can protect this vital market.

Under the IRA, small molecules now face price negotiation at year 9 instead of year 13, shrinking the window companies need to sell exclusively and recoup the hundreds of millions they invest in each new therapy. Jocelyn Ulrich, MPH (Vice President, Innovation Policy at PhRMA)